---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004074"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T19:52:52.570248+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience enters $300K convertible debenture and up to $10M equity purchase agreement

## Summary
- Issued $300K principal convertible debenture to Peak One at $270K purchase price, 8% interest, convertible at $0.52/share.
- Issued warrant to buy 150K shares at $0.75 and 50K commitment shares as inducement.
- Entered equity purchase agreement for up to $10M of common stock in tranches at 97% of market price.
- Proceeds used for working capital and general corporate purposes.
- Registration rights agreement requires filing within 90 days for resale of convertible and warrant shares.

## SEC filing metadata
- accession: 0001493152-23-004074
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223004074/0001493152-23-004074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223004074/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004074
- JSON: https://secwatch.observer/filing/0001493152-23-004074.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004074.txt

## Key facts
- Debt Financings
  INVO Fertility, Inc. incurred convertible notes of $300,000 with Peak One Opportunity Fund, LP at eight percent (8%) per annum maturing February 3, 2024.
  - Instrument: convertible notes
  - Principal: $300,000
  - Counterparty: Peak One Opportunity Fund, LP
  - Rate: eight percent (8%) per annum
  - Maturity: February 3, 2024
  - Event: incurrence
  source text: On February 3, 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into securities purchase agreement (“Purchase Agreement”) with Peak One Opportunity Fund, LP, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $300,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223004074/0001493152-23-004074-index.htm
- Material Agreements
  INVO Fertility, Inc. entered into Purchase Agreement with Peak One Opportunity Fund, LP (effective 2023-02-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Peak One Opportunity Fund, LP
  - Effective: 2023-02-03
  source text: On February 3, 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into securities purchase agreement (“Purchase Agreement”) with Peak One Opportunity Fund, LP, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $300,000 (the “Debenture”) for a purchase price of $270,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223004074/0001493152-23-004074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.